Jashwanth Raj Jagadeesh Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jashwanth Raj Jagadeesh Kumar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Agnishwar Girigoswami
Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, TN-603103, India
1 shared publication - Devadass Jessy Mercy
Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chettinad Health City, Kelambakkam 603103, India
1 shared publication - Jayaprakash Suresh
Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chettinad Health City, Kelambakkam, Chennai 603103, India
1 shared publication - Koyeli Girigoswami
Medical Bionanotechnology Laboratory, Department of Obstetrics and Gynaecology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai 602105, India
1 shared publication - Saranya Udayakumar
Medical Bionanotechnology Lab, Department of Obstetrics and Gynecology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, India
1 shared publication - Shangavy Pandiarajan
Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Chettinad Health City, Kelambakkam 603103, India
1 shared publication
Latest Publications
- Open Access
Revolutionizing Cancer Vaccine: The Power of Advanced Nanotechnology
Developing an effective vaccine that is safer is the main focus in the field of cancer immunotherapy. Among other therapeutic approaches, cancer nanovaccination is formulated to deliver tumor adjuvant or antigen to the antigen-presenting cells (APCs) to prevent cancer relapse and metastasis. It has shown excellent efficacy in inhibiting cancer growth. Herein, we discussed various forms of nanovaccines, including lipid-based nanovaccines, metal-based nanovaccines, carbon nanotube-based nanovaccines, PLGA-based nanovaccines, exosome-based nanovaccines, dendritic cell-based nanovaccines, and self-adjuvant nanovaccines in cancer immunotherapy, including their therapeutic effect. We expect that the investigated content will provide a valuable reference for future research and the development of nanovaccines for cancer treatment.
Open AccessRevolutionizing Cancer Vaccine: The Power of Advanced Nanotechnology
Developing an effective vaccine that is safer is the main focus in the field of cancer immunotherapy. Among other therapeutic approaches, cancer nanovaccination is formulated to deliver tumor adjuvant or antigen to the antigen-presenting cells (APCs) to prevent cancer relapse and metastasis. It has shown excellent efficacy in inhibiting cancer growth. Herein, we discussed various forms of nanovaccines, including lipid-based nanovaccines, metal-based nanovaccines, carbon nanotube-based nanovaccines, PLGA-based nanovaccines, exosome-based nanovaccines, dendritic cell-based nanovaccines, and self-adjuvant nanovaccines in cancer immunotherapy, including their therapeutic effect. We expect that the investigated content will provide a valuable reference for future research and the development of nanovaccines for cancer treatment.